NK
Nadav Kidron Esq.
President, CEO & Executive Chairman
Chairman
born 1974comp · ₪1,065,391
LOADING SNAPSHOT
Fetching the books…
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.
For commercial pharma: watch patent cliffs and competition. For pre-revenue biotech: cash runway and trial readouts.
Not enough positive signals yet. Track for re-rating or fundamental improvement.
| Period | Revenue | Gross profit | Operating income | Net income | Net margin |
|---|---|---|---|---|---|
| 2021-08-31 | — | — | — | — | — |
| 2022-12-31 | ₪2.70M | — | ₪-40.60M | ₪-36.56M | -1352.6% |
| 2023-12-31 | ₪1.34M | — | ₪-15.77M | ₪5.53M | 412.3% |
| 2024-12-31 | — | — | ₪-12.78M | ₪-19.06M | — |
| 2025-12-31 | ₪2.00M | ₪13.00K | ₪-15.09M | ₪64.05M | 3202.5% |
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.